Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Endocr Relat Cancer. 2017 Apr;24(4):157–170. doi: 10.1530/ERC-16-0138

Figure 9.

Figure 9

Enzalutamide increases IFN-γ and stem cell marker expression in CAFs and prostate cancer cells. A, RT-qPCR results of IFN-γ expression in CAFs treated with 5 or 25 μM enzalutamide or no treatment (NT) control. B, RT-qPCR results of Oct4, Sox2 and Nanog expression PC3 cells co-cultured with CAFs and treated 5 or 25 μM enzalutamide for 24 hours. *, p<0.05. Representative results are presented from ≥ 3 independent replicates.